NEW YORK (360Dx) – Emosis, BioRap Technologies, and Rambam MedTech said today that they have entered into an exclusive license agreement to develop and commercialize a microparticle biomarker hypercoagulation kit for several indications.
The license is based on technology developed by researchers at the Rappaport Institute at the Technion-Israel Institute of Technology and Rambam Healthcare Campus, an academic hospital serving more than 2 million residents in northern Israel.
The technology may enable measurement of microparticle biomarkers that identify and monitor patients at high risk of coagulation complications, the firms said.
Under the terms of the agreement, Emosis will use its knowledge and IP to develop a biomarker, or biomarkers, as part of a commercial kit, and BioRap Technologies and Rambam MedTech will perform supporting research at the Rappaport Institute and Rambam Healthcare Campus.
The kit is expected to predict potential thrombotic risk.
Financial terms of the deal were not disclosed.
Emosis board member Frédéric Allemand said in a statement that the licensed technology is especially important in assessing blood clotting risk in cancer, "since microparticles of tumor origin increasingly appear as biomarkers of hypercoagulation in malignancies."
Emosis leverages flow cytometry technology for research into cell-based hemostasis, with a focus on microparticles, the firms said.
Rambam MedTech is the technology transfer company for Rambam Healthcare Campus, and BioRap is the Rappaport Institute's technology transfer company.